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Abstract
Background: Although CD4 cell count monitoring is used to decide when to start antiretroviral therapy in patients with HIV-
1 infection, there are no evidence-based recommendations regarding its optimal frequency. It is common practice to
monitor every 3 to 6 months, often coupled with viral load monitoring. We developed rules to guide frequency of CD4 cell
count monitoring in HIV infection before starting antiretroviral therapy, which we validated retrospectively in patients from
the Swiss HIV Cohort Study.
Methodology/Principal Findings: We built up two prediction rules (‘‘Snap-shot rule’’ for a single sample and ‘‘Track-shot
rule’’ for multiple determinations) based on a systematic review of published longitudinal analyses of CD4 cell count
trajectories. We applied the rules in 2608 untreated patients to classify their 18 061 CD4 counts as either justifiable or
superfluous, according to their prior $5% or ,5% chance of meeting predetermined thresholds for starting treatment. The
percentage of measurements that both rules falsely deemed superfluous never exceeded 5%. Superfluous CD4
determinations represented 4%, 11%, and 39% of all actual determinations for treatment thresholds of 500, 350, and
2006106/L, respectively. The Track-shot rule was only marginally superior to the Snap-shot rule. Both rules lose usefulness
for CD4 counts coming near to treatment threshold.
Conclusions/Significance: Frequent CD4 count monitoring of patients with CD4 counts well above the threshold for
initiating therapy is unlikely to identify patients who require therapy. It appears sufficient to measure CD4 cell count 1 year
after a count .650 for a threshold of 200, .900 for 350, or .1150 for 5006106/L, respectively. When CD4 counts fall below
these limits, increased monitoring frequency becomes advisable. These rules offer guidance for efficient CD4 monitoring,
particularly in resource-limited settings.
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Introduction
The CD4 lymphocyte count, currently regarded as the best
prognostic marker for the development of AIDS, is a major
criterion to decide on initiation of antiretroviral therapy. In
Western countries therapy for HIV-1 infection is recommended
when the CD4 count falls below 3506106/L, still above the cut-off
of 2006106/L that strongly predicts AIDS, while evidence from
non-randomized studies support treatment initiation below
5006106/L [1]. Other patient characteristics may encourage
earlier initiation: very high counts of circulating viral particles
(over 100 000 copies/mL), rapidly falling CD4 counts (more than
1006106/L per year), long-lasting inflammatory symptoms or
comorbidities [1]. Postponing treatment would otherwise be
traditionally recommended [2]. The current trend is however to
offer treatment to patients before their CD4 count reaches
concerning levels, to prevent the deleterious effects of uncontrolled
HIV-1 virus proliferation, which is possibly more hazardous than
the albeit non-negligible adverse effects of antiretroviral drugs
[3,4,5,6]. In countries with limited resources, a threshold CD4
count of 2006106/L is commonly used, although recent guidelines
and observations also suggest earlier treatment [7,8].
While a patient’s CD4 count is above whatever threshold at
which treatment will be started, repeated monitoring of the count
is necessary. However, the frequency with which such monitoring
should be undertaken is not currently clear, and monitoring
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strategies have not been evaluated in clinical trials. Guidelines do
not give explicit recommendations about monitoring frequency
during the pre-treatment phase [1], although most clinicians
measure the CD4 count once every 3–6 months and some also
monitor viral load. Overuse of costly determinations is undesir-
able. However, timely introduction of antiretroviral therapy is
essential in preventing AIDS and death, and underuse of
monitoring in developing countries has detrimental consequences
[9,10]. Two recent simulation studies concluded that improved
HIV detection and pre-treatment CD4 monitoring in resource-
poor settings could save several life-years per person taking
antiretroviral treatment and could be cost-effective by preventing
opportunistic infections [11,12,13]. Observations from the Nether-
lands have shown that under-screening and under-monitoring are
also problematic in Western countries [14].
Our interest in evidence-based monitoring in chronic medical
conditions [15] led us to analyse critically the performance of CD4
cell counts and viraemia in monitoring the pre-treatment phase of
HIV infection. Our aim was to develop rational recommendations
for the desirable monitoring frequency of those markers before
therapy, based on published data, and to validate them in a cohort
of treatment-naı¨ve patients.
Methods
Literature review
We conducted a systematic review of the natural evolution and
variability in CD4 cell count and viral load, to base our decision
rules on the best evidence available from observational studies.
Our aim was to summarize suitable descriptors of the longitudinal
evolution of both these markers in HIV-infected patients followed
up in prospective cohorts while receiving no antiretroviral
treatments. We searched Medline and EMBASE for ‘‘CD4 OR
viraemia OR viral load’’, associated with ‘‘regression OR
longitudinal OR slope OR monitoring’’. We also examined the
bibliographies of all relevant papers. The literature search was
conducted in 2008 and updated in 2010. From among various
statistical approaches to longitudinal analysis of HIV-1 biomark-
ers, we chose the most widely used and readily applicable, based
on mixed-effects (multilevel) linear modelling. For CD4 counts, a
majority of analyses used square-root transformation and thus only
those ones were included; for viral load all used logarithmic
transformation. The population parameters describing the evolu-
tion of biomarkers of HIV-1 were extracted, averaged, and
rounded. Their prognostic value for the development of AIDS and
prediction of death has been addressed in a large meta-analysis
[16].
Elaboration of monitoring rules
Our literature review confirmed that a mixed-effects linear
model of square-root transformed CD4 counts was most often
used to describe individual trajectories in untreated patients,
beyond the acute changes observed during the few months after
primary infection. According to this model, the square root of the
CD4 count falls along a linear mean trajectory starting from a
subject-specific baseline (set point ai) and is characterized by a
subject-specific slope (decline rate bi); actual CD4 counts depart
from this line because of random fluctuations, laboratory
imprecision, and model incomplete accuracy. The subject-specific
baseline (ai) and slope (bi) are considered as random variables
normally distributed around average population values (a and b),
while the deviations of actual CD4 counts from the subject-specific
line are considered to be independently and normally distributed
around zero. The subject’s specific slope and intercept represent
the ‘‘signal’’ hidden by the ‘‘noise’’ of within-subject fluctuations.
As the fall in CD4 count depends on the individual slope and the
time interval, measurements made close together capture only
short-term variability and contain little information about the true
slope. On the other hand, multiple determinations will refine
evaluation of the subject’s true current state, which may be
advantageous in making therapeutic decisions, especially near the
threshold for starting treatment. Monitoring decisions will
therefore vary according to the distance of the patient from the
threshold for antiretroviral treatment. The definition of such a
threshold represents a peculiar aspect of CD4 monitoring [17].
We therefore designed two rules to guide decisions on CD4
monitoring frequency, detailed in Appendix S1 and illustrated in
Figure 1:
‘‘Snap-shot rule’’. The first rule applies to a single CD4
measurement. The aim is to determine the time to the next
observation, which has a given probability of being below
the decision threshold value; in other words, to determine a
time at which the likelihood of finding a clinically relevant
result becomes non-negligible. If the observation at this time
does not reach the decision threshold, the rule can be
applied recursively and will estimate shorter and shorter
intervals until the rule loses its usefulness; then either the
Track-shot rule below or frequent CD4 monitoring become
necessary. The Snap-shot rule is thus mainly designed for
relatively high CD4 cell counts.
‘‘Track-shot rule’’. If multiple CD4 measurements have
been performed in a subject, it may be worth using all those
results to estimate the individual trajectory. A Bayesian
approach is used to combine individual observations with
published population estimates, directly inspired by a
method developed for interpreting serum digoxin concen-
trations [18]. Once maximum likelihood estimates of the
subject’s specific slope and intercept have been determined,
an approach very similar to the Snap-shot rule can be used to
determine the suitable time for scheduling the next
measurement, i.e. the nearest likely time when a new
observation will reach the decision threshold with a given
probability. As before, as CD4 counts come near to the
decision threshold, this rule loses its usefulness and frequent
CD4 monitoring becomes necessary.
Both rules can be applied either using global population values
for the average baseline and slope, or taking into account
individual characteristics that affect the CD4 trajectory, such as
the viral load and age. The average population parameter values,
their inter-individual variances, and the residual variance of square
root CD4 count departures from a linear trajectory were drawn
from the literature review.
Viral load is not commonly used as a biomarker for disease
progression, due to prominent variability and absence of clear time
trend over the asymptomatic phase of HIV-1 infection in a fair
number of patients. Moreover, viral load is not usually interpreted
in terms of a decision threshold for starting antiretroviral therapy.
This leaves little role for specific rules to guide determination
frequency, as confirmed by our attempt to apply a similar
approach to this marker (Appendix S2 and Figure S1).
Validation study
To test their performance with actual clinical data, we applied
both decision rules to an unselected series of HIV-1 infected
CD4 Monitoring Prior to ART
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patients. The multi-centre Swiss HIV Cohort Study (SHCS),
established in 1988, includes about a half of all HIV-positive
individuals in Switzerland (www.SHCS.ch). Detailed clinical data
are obtained from the subjects on recruitment and then at visits
scheduled at least 6-monthly; all CD4 and viral load determina-
tions are entered into the database. All patients give their written
consent to epidemiological analysis of their follow up data. This
validation study was approved by the SHCS scientific board.
Of the 9570 subjects recruited during the past 12 years (1
January 1996 to 31 May 2008), 5551 have undergone CD4 and
viral load monitoring before starting antiretroviral therapy. The
data from patients with at least two such recorded values were used
to validate the rules outlined above, applied recursively from the
first value. To prevent selection bias in favour of slow progressors,
cases were included only if their first biomarker value was
recorded after 1996. We did not adjust for right truncation due to
treatment initiation, interruption in a subject’s follow-up beyond
2008, or other causes. For all included cases, we used the rules to
determine an optimal length of time between measures, based on
one or more initial measures and predefined treatment decision
thresholds. We started from the first CD4 count recorded, with P
set to 0.05 (i.e. re-testing was deemed superfluous before having at
least a 5% chance to reach the treatment initiation threshold). We
also tested both rules with P set to 0.1. Subsequent CD4
determinations performed before the time indicated by the rule
(tnext) were counted, compared with the threshold, and discarded as
superfluous. The Snap-shot rule was then reiterated on the next
justifiable (i.e. non-superfluous) measurement, done after tnext, and
so on. The Track-shot rule took into account only previous CD4
values not discarded. Treatment thresholds were set at CD4
counts of 200, 350, and 5006106/L.
The main objective of the study was to verify the adequacy of the
classification of CD4 measures by both rules. Concretely, we aimed
to check that not more than 5% of the CD4 results deemed
superfluous would actually reach the threshold, using a predefined P
level of 0.05; or not more than 10% using a P of 0.1. Calculations
were performed using Excel (Microsoft, Redmond WA, 2003) and
STATA software (v. 10, StataCorp, College-Station TX, 2007).
Results
Literature review
Most published descriptions of CD4 cell counts and viral load
evolution in untreated HIV infection come from cohort data. We
screened 149 abstracts addressing the topic of the rate of fall in CD4
counts in untreated HIV-1 infection, and we identified 40
publications that described mathematically the natural evolution
of CD4 counts in untreated HIV-1 infected patients. Among them,
11 did not provide usable parameters, while 19 used longitudinal
models, data transformations, or parameterizations that were not
relevant to our approach (see PRISMA Flow Diagram S1). Thus,
we included 8 analyses that provided suitable estimates of
parameters describing the fall in CD4 count in the square-root
scale according to a mixed-effects linear model [19,20,21,22,
23,24,25,26] (Table 1); we also included the summary estimates
from two similar reviews [11,27]. CD4 count has high variability
between measures, even taken a few hours or days apart, with
coefficients of variation of 13–26% [28,29]. Square-root transfor-
mation simultaneously renders average trajectories approximately
linear and residual errors approximately Gaussian, and is the
method that has been used most often with CD4 count data [20,30].
Patients are reported to differ regarding both their baseline (set
point) and slope (rate of fall) of CD4 count; non-progressors remain
stable over years [31] while rapid progressors lose large numbers of
cells over short periods [32]. Slopes tend to be steeper in individuals
who start from a high baseline, and are mainly correlated with viral
load [32,33,34,35] and increasing age [19,36]; they are also affected
by HIV strain [37], transmission route [38], gender [35], race [35],
pregnancy [39], genetics [40], and immune reactivity [41].
However, all those factors explain only a small percentage of the
overall variability in the rate of fall in CD4 count (less than 10% for
viral load and age) [42]. Average CD4 decline rates have been
reported to be similar between African and Western countries [43],
although recent observations suggest slightly slower rates in non-
white individuals [44].
There was a moderate degree of heterogeneity across the
estimates shown in Table 1. To elaborate our general monitoring
Figure 1. Illustration of CD4 monitoring decision rules. The Snap-shot rule (left) uses a single observation Yobs (square root transformed) of the
biomarker at time tobs. The Track-shot Rule (right) uses Yobs plus one or more previous observations Y21, Y22 etc. available at times t21, t22 etc. The
suitable time for next measurement, tnext, is when the predicted value has some minimal probability P to reach the decision limit for antiretroviral
therapy YART. Appropriate standard normal deviates zP are used to weight the within-subject and between-subject dispersions, se and sb
respectively, according to the level chosen for P. The relevant prediction therefore depends on a worst-case scenario (Ywst) rather than average
population prediction (Ypred). This illustration is schematic, as it is variances that are actually summed, not standard deviations.
doi:10.1371/journal.pone.0018578.g001
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rules, we simply took the rounded average values. We also
performed sensitivity analyses to check the robustness of the rules
towards alteration in the parameters.
CD4 monitoring recommendations
The operation of the Snap-shot rule to determine the suitable time
for CD4 remeasurement is illustrated in Figure 2 using the
‘‘variogram’’ approach [45] based on equation 3 above. It shows
the lowest CD4 count that a subsequent measurement is expected
to reach with a preset probability, P, for a given result. The essence
of this rule can be represented in a nomogram (Figure 3). The
Snap-shot rule justifies delayed CD4 measurement for higher values
observed:
N With a treatment threshold count of 2006106/L, under 5% of
individuals are expected to reach the threshold within 6
months after a count of 6006106/L, 1 year after 6506106/L,
1.5 years after 7006106/L, 2 years after 7706106/L, 3 years
after 9506106/L, or 4 years after 11006106/L.
N A threshold of 3506106/L has less than a 5% chance of being
reached 6 months after a value of 8406106/L, 1 year after
9006106/L, 1.5 years after 9706106/L, 2 years after
10506106/L, or 3 years after 12506106/L.
N A threshold of 5006106/L has less than a 5% chance of being
reached 6 months after a value of 10606106/L, 1 year after
11406106/L, 1.5 years after 12206106/L, or 2 years after
13006106/L.
The rule loses its usefulness in the presence of low to
intermediate CD4 counts (below 550, 785, and 10006106/L for
the three respective decision thresholds at P = 0.05, and below 460,
675, and 8806106/L at P = 0.1).
The operation of the Track-shot rule cannot be summarized in a
chart, since it is based on serial measurements. This rule
individualizes to a reasonable extent the mean expectation of the
CD4 trajectory with regard to previous results. It also reduces the
width of the prediction interval when many results have been
recorded. But even for a trajectory defined with high precision by
Table 1. Published estimates of CD4 cell count decay rate and variability in untreated HIV-infected individuals.
Reference b sb a sa se rab N?n duration
DeGruttola 1991 [20] 2.1 1.1 33 4 3 20.9 495?5 3
Lange 1992 [23] 1.6 0.6 30 2 – 20.5 327?8 3.5
Faucett 1996 [21] 2.3 2.4 25 10 2.7 20.6 109?6 4.1
Lepri 1997 [22] 1.7 2.8uu 26 6 – – 1021 .10
Touloumi 1998 [19] 1.4 1.2 25 5 – – 137?9 10
Laurent 2002 [24] 1.3 – 26 – – – 331?3 2
CASCADE 2003 [25] 1.3 to 1.7* 1.4 23 to 29u 6 3 20.4 5739?9 5.2
Taffe´ 2008 [26] 2.1 1.2 30 3 6 20.4 4217?6 3
Phillips 2007 [27] 0 to .2{ 0.8 39 2 – – (review)
Hallett 2008 [11] 1.3 to 2{ 1 26 1 (50**) – (review)
Average 1.8 1.2 30 5 4 20.5 (rounded values)
Parameters derived from linear mixed effect model in the square root scale. b: slope and sb: inter-individual slope variability in (10
6/L)0.5/year; a: intercept, sa: inter-
individual intercept variability and se: intra-individual variability in (10
6/L)0.5; rab: correlation between a and b; N: number of individuals, n: average number of samples
per individual; average duration of observation in years.
*slope according to age (15–20: 1.30, 20–30: 1.53, 30–40: 1.73, .40: 1.67) and to symptoms at pre-infection (present: +0.26).
uintercept depending on subgroup (sex, age, intravenous drug use or haemophilia).
{slope depending on viral load (0 at ,103, then 0.016, 0.04, 0.12, 0.4, 0.8 and 1.6 for every 100.5 step up to 2.0 at .106/mL), age (+0.007/year), X4-virus shift (present:
+0.25).
{slope depending on age (,35: 1.3, .35: 2).
**standard deviation of an uniform distribution in the untransformed CD4 count scale.
uuoutlier value discarded from average calculation.
doi:10.1371/journal.pone.0018578.t001
Figure 2. Variogram for the Snap-shot rule. The Snap-shot rule is
applied to an initial CD4 cell count of 7506106/L, observed at time = 0.
It shows the lowest value that a subsequent measurement can be
expected to reach with a probability of 5% (dashed line) or 10% (dotted
line). The continuous line indicates the CD4 trajectory predicted for an
average patient. The average curve will take 7.3 years to reach the
2006106/L threshold (horizontal line); however, biological variability
makes this outcome possible within 2 years for one patient in 20, and at
3 years for one patient in 10.
doi:10.1371/journal.pone.0018578.g002
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numerous points, this rule loses its usefulness once intra-individual
variability makes it possible for the next point to reach the
threshold (respectively below 430, 640, and 840 for the three
thresholds at P = 0.05, and 370, 570, and 755 at P = 0.1). An Excel
spreadsheet implementing both the Snap-shot rule and the Track-shot
rule is available as supporting information (see Excel Tool S1).
Validation of the CD4 monitoring rules
In total, 2608 patients from the Swiss HIV Cohort Study were
entered into the validation study (Table 2). They had 18 061 CD4
measurements over a median (interquartile range, IQR) follow-up
of 559 (182–1182) days, consecutive measurements being
separated by 105 (85–171) days. The CD4 cell counts spread
around a median of 427 (310–593)6106/L, while their square-root
transforms followed a fairly symmetric, bell-shaped distribution,
with a mean (SD) of 20 (6.2) (cell count)0.5. Two thirds of the
patients started antiretroviral therapy before May 2008.
Compared with the study patients, those who could not be
included because they lacked repeated CD4 testing were slightly
more often women (66%, P = 0.06), older (37, IQR 32–42 years,
P,0.001), and intravenous drug users (29% vs 18%, P,0.001).
Above all, they had significantly lower initial CD4 counts, with a
median of 250 (111–430, P,0.001), and higher initial viral loads,
with a median of 51 800 (10 400–175 000, P,0.001). Among
them, 2689 (91%) started antiretroviral therapy soon after their
single off-treatment CD4 determination, which presumably often
represented a main criterion for treatment decision.
Application of the monitoring rules, illustrated in Figure 4,
shows that the frequency of CD4 determinations can be kept low
while high counts are observed. In most situations, the Snap-shot
rule and the Track-shot rule give similar results.
We applied both rules iteratively to CD4 counts in the patients
in the validation study. Table 3 summarizes the evaluation of the
15 453 non-initial CD4 values according to the rules, each run at
two levels of probability (P = 0.05 and 0.1) and at three treatment
decision thresholds (200, 350, and 5006106/L). The Snap-shot rule
declared fewer measurements superfluous than the Track-shot rule
for a threshold of 2006106/L, an equal amount for 3506106/L,
and more for 5006106/L. However, the corresponding absolute
counts fell dramatically on increasing the threshold, as expected.
The analysis confirmed that the percentage of CD4 results that
were actually below the threshold value among determinations
deemed superfluous was always lower than the preset probability
level P used to run the rules, moderately so for the 350 and
5006106/L thresholds but markedly for the 2006106/L thresh-
old. There were 4905 superfluous tests in 1024 patients, taken 322
(IQR 139–605) days before the time indicated by the Snap-shot rule
run at P = 0.05 for the 2006106/L threshold; for the 3506106/L
threshold, there were 1724 superfluous tests in 421 patients,
requested 287 (122–555) days in advance; and for the 500 cells/mL
threshold, 625 superfluous tests in 192 patients, requested 256
(102–482) days in advance. When we restricted the analysis to the
CD4 results obtained within 63 months of the date indicated as
suitable for re-measurement by the rules, the absolute numbers of
values became smaller (219–2393), while the percentages of falsely
superfluous CD4 results remained below the preset probability
(0.68%, 2.93%, and 4.38% for the Snap-shot rule at P = 0.05 at the
200, 350, and 5006106/L thresholds respectively). Very similar
results emerged for the Track-shot rule (not detailed).
There was no advantage in using the rules with individualized
slopes modified according to age, initial viral load, or HIV
infection route (not detailed). The Track-shot rule evaluated average
(SD) posterior slope estimates of 1.67 (0.51) (cell count)0.5/year,
and intercept estimates of 26 (4.3) (cell count)0.5. Its use with a non-
informative prior intercept gave very similar results; conversely, a
non-informative prior slope severely compromised the validity (not
detailed).
Sensitivity analyses
Both rules were robust towards changes in parameter values,
which did not markedly affect the outcomes. For the Snap-shot rule,
a 25% reduction in the population average slope (b) translated into
a few more measurements being declared superfluous (35%
instead of 32% for a threshold of 250 cells/mL, 4.6% instead of
4.1% for 500 cells/mL); conversely, increasing b by 25% slightly
reduced this percentage (29% instead of 32%, and 3.6% instead of
Figure 3. Nomograms for the Snap-shot rule. These nomograms
show the time to wait before the next CD4 count determination as a
function of the actual observation, at two decision thresholds to start
antiretroviral therapy, with varying probabilities of observing a value at
this threshold. The 50% lines correspond to average population
predictions. The arrows illustrate the rule applied to an intial count of
10006106/L, giving about 1.7 years to reach a count of 3506106/L with
a 5% chance, and about 3.4 years to reach a count of 2006106/L.
doi:10.1371/journal.pone.0018578.g003
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4.1%); these manipulations minimally affected the rate of falsely
superfluous results (all absolute changes ,0.8%). Increasing or
decreasing the slope dispersion (sb) by 25% had little effect on the
number of either superfluous measurements (absolute changes
,1.3%), or falsely superfluous results (absolute changes ,0.4%).
Modifying intra-patient variability (se) had more dramatic effects:
a 25% reduction in se increased both the number of superfluous
measurements (47% instead of 32% for a threshold of 250 cells/
mL, 8.1% instead of 4.1% for 500 cells/mL) and the rate of falsely
superfluous results (0.9% instead of 0.5% for a threshold of 250
cells/mL, 5.7% instead of 4.8% for 500 cells/mL), while a 25%
increase in se had the opposite effect. Despite this, none of the
actual percentages of falsely superfluous rates, calculated with a
preset P value of 0.05, exceeded 5.7%. The Track-shot rule was not
more sensitive to changes in the choice of parameter values (not
detailed).
Discussion
Monitoring CD4 cell counts in asymptomatic HIV-1 infected
patients to decide when to start antiretroviral therapy is
unanimously recommended and is cost-effective [11,12]. Howev-
er, no recommendations have yet been formulated regarding the
optimal frequency of CD4 monitoring, which most UK practi-
tioners perform every 3–4 months [46]. Based on a review of
published observations describing average CD4 decline rates and
variability in populations of untreated HIV-1 infected patients, we
developed two decision rules aimed at guiding CD4 monitoring
decisions [17]. The Snap-shot rule applies to a single measurement.
The Track-shot rule takes into account a series of CD4 results in a
given patient. We validated both rules using CD4 counts collected
before the start of therapy in a large cohort of HIV-1 infected
patients. The rules proved reliable and robust and can therefore be
used to guide the management of asymptomatic patients.
We used a similar approach to evaluate the performance of
repeated viral load determination based on a systematic literature
review (see Appendix S2). It confirmed that this measurement has
a limited role in monitoring patients who are not taking
antiretroviral therapy, as others have found [12,47].
Various approaches have been used to describe the average
trend of CD4 or viral load and their inter- and intra-patient
variability [48]. Since the early 1990s, mixed-effects modelling has
progressively prevailed [20,30]. Both of our rules use this
approach, which minimizes contamination of the parameters that
describe individual trajectories by intra-individual fluctuations and
measurement errors. It appropriately shrinks the estimation of
slope variability, thus clearly improving predictive performance
[30].
We initially expected that the Track-shot rule would outperform
the Snap-shot rule, since it adduces more information. However,
except for patients starting from high CD4 levels and targeting a
low treatment threshold (2006106/L), the Track-shot rule was not
superior (Table 3). Relaxing prior assumptions regarding the
intercept of CD4 trajectory (a) changed nothing (though it is
theoretically appropriate to do so, owing to uncertainty in the
HIV-1 seroconversion date in many patients). We attribute this
important finding to the fact that the fall in CD4 count with time is
largely dominated by large intra-individual variability (se), which
combines biological fluctuation, laboratory imprecision, and
model inaccuracy; inter-individual slope variability plays the
second role. This is further reflected by the results of our
sensitivity analysis.
The observed rates of false superfluous CD4 tests were below
the preset probability level (P), in particular for the low target
threshold of 2006106/L (Table 3). This is partly due to the more
frequent repetition of CD4 testing in patients with slower rates of
fall in CD4 count, while the most rapidly progressing patients were
Table 2. Description of the subpopulation of patients drawn
from the Swiss HIV Cohort Study for the validation study.
Characteristic
Number of patients 2608
Men, n (%) 1786 (68.5%)
Age, median (IQR) 35 (29–41)
Likely source of HIV infection
Heterosexual contact
Homosexual contact
Intravenous drug use
Other
Unknown
1105 (42.4%)
930 (35.7%)
473 (18.1%)
42 (1.6%)
58 (2.2%)
Days since first HIV positive test, median (IQR) 40 (14–453)
Initial CD4 count, median6106/L (IQR) 426 (286–605)
Initial viral load, median copies/mL (IQR) 24 000 (5100–93 800)
Number of CD4 determinations before
antiretroviral therapy, median (IQR)
5 (3–9)
Initiation of antiretroviral therapy, n (%) 1759 (67%)
Days to initiation of antiretroviral
therapy, median (IQR)
344 (87–889)
Last CD4 count before antiretroviral
therapy, median6106/L (IQR)
239 (166–328)
doi:10.1371/journal.pone.0018578.t002
Figure 4. CD4 cell count data from an illustrative patient. The
Snap-shot rule is applied to the first determination (closed circle) done
1.8 year after positive serology (discovered at time = 0), and indicates to
repeat the test at 3.2 years (dashed arrow), when the CD4 count has 5%
chance to reach 200 cells/mL. The second value actually measured at 3
years is thus declared superfluous and discarded (open circle). The rule
is reapplied to the third value actually measured at 3.6 years, and
designates the 3 next determinations as superfluous. The last 6 values
fall below the threshold to question necessity. The treatment is actually
initiated 7 years after HIV detection, once CD4 counts reach the
threshold of 200 cells/mL. The lines indicate the average population
slope. The Track-shot rule would give fairly similar results, except that it
would indicate the 8th measurement as superfluous (dotted arrow and
grey circle).
doi:10.1371/journal.pone.0018578.g004
CD4 Monitoring Prior to ART
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18578
soon to receive treatment. Besides this right truncation, our
validation population was also affected by selection bias. Indeed, a
significant number of patients with a more active form of HIV-1
infection never underwent off-treatment CD4 monitoring, but
immediately started antiretroviral therapy. This is reflected in the
lower initial CD4 counts and higher viral loads in non-included
patients. This is also in accordance with the fact that the post-hoc
slope estimates given by the Track-shot rule were distributed around
a lower average than we found in our literature review. Such
selection bias actually represents a reassuring argument for
implementing the rules in a clinical setting, where similar selection
bias is likely to occur: our rules, based on average CD4 kinetic
parameters, are thus expected to perform with an extra safety
margin when they are used in patients whose clinical condition
allows treatment to be deferred.
The rules did not perform better when age, initial viral load or
HIV infection route, which are thought to modulate the average
rate of fall in CD4 count, were incorporated. This is probably
because, despite their statistical significance in cohort studies, age
and viral load explain only a tiny part of overall CD4 variability
[34,42].
The consequences of CD4 measurement variability on thera-
peutic decisions were recognized in 1992 by Hoover, who
suggested starting therapy after measuring two consecutive CD4
counts below the decision threshold, instead of one [28]. The
phenomenon of regression to the mean, resulting from oscillation
of values around their long-term trajectory, may be viewed as an
argument for frequent monitoring. However, as we have shown,
analysis of biological variability results in recommendations that
spare measurement resources when frequent monitoring is
unnecessary, in this case after a high CD4 cell count.CD4
monitoring represents only one aspect of the management of HIV-
infected patients who do not require therapy, whose follow-up
frequency should be arranged according to many other factors
(e.g. co-morbidities, prevention of contamination, need for
psychological support).
We found that roughly 11% of all CD4 cell counts performed in
untreated patients were of questionable clinical usefulness, as they
had less than a 5% chance of being under 3506106/L. This
represented 1724 measurements, or a global cost of 93 000 CHF
(J58 000, £47 000, $82 000) for 421 patients. The percentage
would increase to almost 40% with the Track-shot rule at a
treatment threshold of 2006106/L, which was commonly used in
developing countries until very recently. Although there is no
indication that our rules would perform differently in resource-
poor settings, they should be validated in populations differing
from Swiss HIV patients.
Finally, the main limitation of our rules is their inability to
provide guidance for following CD4 cell counts when they start to
approach the threshold for starting therapy. This is a consequence
of the fact that the variability in CD4 count is mainly governed by
the intra-individual component (se). The Snap-shot rule ceases to be
applicable once the variogram meets the treatment threshold
(Figure 2). If there are multiple CD4 determinations, the Track-shot
rule can be used later on, but loses its usefulness once intra-
individual variability makes it likely that an immediately retested
CD4 count will reach the treatment threshold. Beyond this point,
traditional testing at about 3 month intervals is justified. A single
Table 3. Validation of the two rules on all non-initial CD4 cell counts.
Rule: Snap-shot rule Track-shot rule No rule
Probability level: P=0.05 P=0.1 P=0.05 P=0.1
Threshold for
antiretroviral therapy:
Evaluation of informativity: Actual CD4
result:
#200 cells/mL justifiable #200 1154 1112 1144 1069 1179
.200 9394 7126 8268 5313 14 274
superfluous #200 25 67 35 110 –
.200 4880 7148 6006 8961 –
percent superfluous* 32% 47% 39% 59% –
percent #200 among themu 0.5% 0.9% 0.6% 1.2% 7.6%
#350 cells/mL justifiable #350 5153 5108 5152 5118 5196
.350 8576 7416 8653 7358 10 257
superfluous #350 43 88 44 78 –
.350 1681 2841 1604 2899 –
percent superfluous* 11% 19% 11% 19% –
percent #350 among themu 2.5% 3.0% 2.7% 2.6% 33%
#500 cells/mL justifiable #500 9701 9661 9717 9682 9731
.500 5127 4608 5323 4892 5722
superfluous #500 30 70 14 49 –
.500 595 1114 399 830 –
percent superfluous* 4.1% 7.7% 2.7% 5.7% –
percent #500 among themu 4.8% 5.9% 3.4% 5.6% 63%
The 15 453 non-initial CD4 tests in 2608 treatment naı¨ve patients were first classified as either justifiable or superfluous based on the rules, and then compared with the
preset threshold to assess the percentage actually measured below it.
*All 95% confidence band widths ,0.8% (normal approximation for binomial proportions).
uAll 95% confidence band widths ,1.8% (normal approximation for binomial proportions).
doi:10.1371/journal.pone.0018578.t003
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CD4 count below the threshold should be confirmed before
starting antiretroviral therapy. In many cases will the repeat
measure exceed the threshold, allowing further delay before
initiation [28].
In conclusion, both theoretical arguments and observational
evidence suggest that CD4 cell count monitoring, as performed in
HIV-1 infected patients who do not require treatment, is currently
too frequent in those whose CD4 counts are well above the
treatment threshold. Infrequent measurement can safely be
recommended in this subpopulation.
Supporting Information
Figure S1 Variogram for viral load monitoring. This variogram,
based on the Snap-shot rule for an initial determination of a viral
load of 1000 copies/mL (3 log units/mL), shows the highest load
that a subsequent measurement can be expected to reach, with a
probability of 5% (dashed line) or 10% (dotted line). The
continuous line indicates the viral load trajectory predicted in an
average patient, taking about 12 years to increase by 1 log unit.
After 6.7 years one patient in 20, and after 9.2 years one patient in
10, can be expected to have a 2 log unit increase (i.e. to 100 000
copies/mL, arrows).
(TIF)
Appendix S1 Construction of the monitoring rules: statistical
assumptions and mathematical derivations underlying the snap-shot
rule and the track-shot rule.
(PDF)
Appendix S2 Evaluation of viral load monitoring: literature
review and application of the rules to viral load.
(PDF)
Excel Tool S1 An easy-to-use computer tool to assist CD4 cell
count monitoring in HIV infection before starting antiretroviral
therapy. It implements both the snap-shot rule and the track-shot rule
to guide CD4 determination frequency.
(XLS)
PRISMA Flow Diagram S1 Outline of the literature search.
(PDF)
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